BioNexus Gene Lab Corp. (BGLC) Operating income 2018–2025
BioNexus Gene Lab Corp. (BGLC) annual operating income history from SEC filings — each fiscal year as reported.
-$3.0MFY2025 · since FY2018: $59,901 → -$3.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.0M | -88.4% |
| FY2024 | -$1.6M | +39.3% |
| FY2023 | -$2.6M | -790.7% |
| FY2022 | -$291,177 | -127.6% |
| FY2021 | $1.1M | -17.1% |
| FY2020 | $1.3M | +562.0% |
| FY2019 | -$275,705 | -560.3% |
| FY2018 | $59,901 | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More BGLC financial trends
BGLC RevenueBGLC Net incomeBGLC Net marginBGLC Gross profitBGLC Gross marginBGLC Operating marginBGLC Operating cash flowBGLC Free cash flowBGLC Capital expendituresBGLC Return on equityBGLC Stock buybacksBGLC Dividends paidBGLC Total assetsBGLC Total liabilitiesBGLC Shareholders’ equityBGLC overview →